Insights: News
As a diagnostics platform company that provides serious or complex laboratory testing, Mayo Clinic Laboratories is constantly working to advance patient care and broaden access to specialized testing. Learn about the latest news from Mayo Clinic Laboratories here, including new test launches, collaborations, operational updates, and more.
Most recent posts
Christopher Garcia, M.D., shares how secure digital tools, wearable data, and AI can enable more personalized diagnostic pathways, while still keeping clinicians in the driver’s seat.
Mayo Clinic Laboratories has developed a new colorectal cancer test, the MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC), in response to the latest recommendations for testing and treatment from the American Society of Clinical Oncology.
The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST.
The MayoACCESS test ordering application is now available and all technical issues have been resolved. However, if you still encounter issues when logging in to MayoACCESS, clear your browser cache and reboot your computer. Complete the following steps depending on your browser type:
In June 2023, Mayo Clinic Laboratories announced 28 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Due to the upcoming Independence Day holiday on Tuesday, July 4, Mayo Clinic Laboratories' sample pickup and delivery schedules will be altered. To ensure sample viability and minimize test turnaround time delays, we have implemented several adjustments and guidelines.
Mayo Clinic Laboratories’ new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG) provides more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.
A team of researchers has confirmed that neutralizing monoclonal antibody (nMAb) therapies are associated with reduced risk of adverse outcomes of COVID-19 in high-risk populations. The cohort study, published in JAMA, included more than 167,000 nonhospitalized patients from health care systems based in California, Texas, and Utah, and at Mayo Clinic in Rochester, Minnesota.
In May 2023, Mayo Clinic Laboratories announced 22 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Due to the Memorial Day holiday (recognized on Monday, May 29), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure that your specimen vitality and turnaround times are not affected, please plan ahead.
Visit Mayo Clinic Laboratories at booth #2047 to learn about our comprehensive therapeutics test offerings. Developed by board-certified experts in clinical chemistry, molecular, and toxicology testing, our testing is designed to detect and monitor therapeutic and illicit drugs across several relevant specimen types.
In April 2023, Mayo Clinic Laboratories announced 10 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
A medical mystery surrounding a clotting disease spurred a collaboration between Mayo Clinic and University of Michigan Health to develop a new test methodology and the discovery of a previously unknown blood clotting condition.